ArticleSeminars in arthritis and rheumatism2020
TNF-alpha inhibition for the treatment of cardiac sarcoidosis.
Article in Seminars in arthritis and rheumatism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies.The European respiratory journal · 2022Pooled it
- Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management.Open heart · 2026Article
- Granulomas in the Heart: Pathophysiology, Diagnosis, Management, and Outcomes in Cardiac Sarcoidosis.Cureus · 2026Review
- Asthma in Patients With Confirmed Pulmonary Sarcoidosis.Canadian respiratory journal · 2026Review
- Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis.Rheumatology (Oxford, England) · 2025Article
- Narrative review of adalimumab for the treatment of cardiac sarcoidosis.Heart rhythm O2 · 2025Review
- Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies.Reviews in cardiovascular medicine · 2025Review
- Review
- Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.The American journal of cardiology · 2023Article
- Tumor Necrosis Factor-α Inhibitors in Cardiac Sarcoidosis Management: Evaluating Therapeutic Efficacy and Future Directions.The American journal of cardiology · 2023Article
- Diagnostic and therapeutic practices of cardiac sarcoidosis in the United States: a nationwide questionnaire based study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Assessment of treatment response in cardiac sarcoidosis based on myocardialFrontiers in immunology · 2023Article
- Adalimumab for the treatment of cardiac sarcoidosis with multiple arrhythmias.ESC heart failure · 2022Article
- Adalimumab in the treatment of cardiac sarcoidosis: Single center case series and narrative literature review.Respiratory medicine case reports · 2022Article
- Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.Journal of cardiac failure · 2022Review
- State-of-the-Art Treatments for Sarcoidosis.Methodist DeBakey cardiovascular journal · 2022Review
- Cardiac sarcoidosis: Two case reports.Clinical case reports · 2021Article
- Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience.Journal of cardiac failure · 2021Article
- Case Report: TNFα Antagonists Are an Effective Therapy in Cardiac Sarcoidosis.Frontiers in cardiovascular medicine · 2021Article
- Management of Cardiac Sarcoidosis in 2020.Arrhythmia & electrophysiology review · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTumor necrosis factor alpha (TNF-α) inhibitors are increasingly being used for treating refractory cardiac sarcoidosis. There is a theoretical risk, however, that these therapies can worsen heart failure, and reports on efficacy and safety are lacking.
methodsWe conducted a retrospective review of all cardiac sarcoidosis patients seen at Stanford University from 2009 to 2018. Data were collected on patient demographics, diagnostic testing, and treatment outcomes.
resultsWe identified 77 cardiac sarcoidosis patients, of which 20 (26%) received TNF-α inhibitor treatment. The majority were treated for progressive heart failure or tachyarrhythmia, along with worsening imaging findings. All TNF-α inhibitor treated patients demonstrated meaningful benefit, as assessed by changes in advanced imaging, echocardiographic measures of cardiac function, and prednisone use.
conclusionsA large cohort (n = 77) of cardiac sarcoidosis patients has been treated at Stanford University. Roughly one-fourth of these patients (n = 20) received TNF-α inhibitors. Of these patients, none had worsening heart failure and all saw clinical benefit. These results help support the use of TNF-α inhibitors for the treatment of cardiac sarcoidosis based on real-world evidence and highlight the need for future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.